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Abstract: BACKGROUND: Although rare, bullous pemphigoid (BP) is the most common autoimmune blistering dis-
ease. Recent studies have shown that patients with bullous pemphigoid are more likely to have neurological and
psychiatric diseases, particularly prior to the diagnosis of bullous pemphigoid. OBJECTIVE: The aims were: (i) to
evaluate the demographic and clinical features of bullous pemphigoid from a database of patients at a
Portuguese university hospital and (ii) to compare the prevalence of comorbid conditions before the diagnosis of
bullous pemphigoid with a control group. METHODS Seventy-seven patients with bullous pemphigoid were
enrolled in the study. They were compared with 176 age- and gender-matched controls, which also had the same
inpatient to outpatient ratio, but no history of bullous or cutaneous malignant disease. Univariate and multivari-
ate analyses were used to calculate odds ratios for specific comorbid diseases. RESULTS: At least one neurologic
diagnosis was present in 55.8% of BP patients compared with 20.5% controls (p<0.001). Comparing cases to con-
trols, stroke was seen in 35.1 vs. 6.8%, OR 8.10 (3.80-17.25); dementia in 37.7 vs. 11.9%, OR 5.25 (2.71-10.16); and
Parkinson's disease in 5.2 vs. 1.1%, OR 4.91 (0.88-27.44). Using multivariate analysis, all diseases except
Parkinson's retained their association with BP. Patients under systemic treatment were eight times more likely to
have complications than those treated with topical steroids (p< 0.017). CONCLUSIONS: The results of this study
substantiate the association between BP and neurological diseases. In addition, they highlight the potential com-
plications associated with the treatment of BP.
Keywords: Comorbidity; Nervous system diseases; Neurologic manifestations; Pemphigoid, bullous; Portugal
Received on 05.02.2013.
Approved by the Advisory Board and accepted for publication on 06.04.2013. 
* Work performed at the Hospitais da Universidade de Coimbra (HUC) – Coimbra, Portugal.
Financial Support: None
Conflict of Interest: None
1 Coimbra University Hospital, Portugal.
©2014 by Anais Brasileiros de Dermatologia
INTRODUCTION
Bullous pemphigoid (BP) is the most common
autoimmune blistering disease and predominantly
affects the elderly.1-3 However, on rare occasions, it can
be present in young adults and children.4 Both gen-
ders are equally affected. The annual incidence of BP
has been estimated to range from 2 to 14 new cases per
million people.1,3,5-6 Its incidence is expected to rise as a
consequence of population ageing. A recent study in
France found a 3-fold increase in the annual incidence
of BP over the last 15 years, with 21.7 new cases per
million inhabitants.7
BP is characterized by the presence of circulat-
ing IgG autoantibodies directed against two proteins
of the basement membrane zone, bullous pemphigoid
antigens 1 and 2 (BPAG1 and BPAG2), which are
detectable by both direct and indirect immunofluores-
cence. However, pathogenesis is still not completely
understood. Previous studies have suggested a rela-
tionship between BP and comorbid conditions like
neurological and psychiatric diseases, diabetes melli-
tus, and malignancy.8-12 Recently, a prospective case-
control study, which evaluates risk factors for BP,
identified neurological disorders, namely dementia
and Parkinson’s disease, psychiatric disorders (unipo-
lar and bipolar disorders), bedridden condition, and
chronic use of several drugs, as risk factors for BP.13
Systemic corticotherapy (prednisone 0.5-1 mg
per kilogram of body weight per day) is considered
the standard treatment, but serious adverse effects can
occur, including death, particularly in elderly
patients.14-18 In  spite of the progress in BP treatment,
the mortality rate of these patients can be up to six-
fold higher than in the general population.7
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In 2002, Joly  et al conducted a large controlled
clinical trial, which demonstrated that high potency
topical steroids improve survival in patients with exten-
sive BP, as compared with oral corticosteroid therapy.19
Objective
The primary endpoint of the present study was
to determine the prevalence and association of comor-
bid conditions with BP in patients who had medical
attendance at our hospital.
MATERIALS AND METHODS
This case-control study was approved by the
research ethics board of Coimbra University Hospital.
Between January 1998 and December 2010, we identi-
fied, in our department, all individuals who had
undergone a histological procedure (n=97) on the basis
of clinical suspicion of BP. From this initial cohort, we
performed a manual chart review, abstracting medical
records individually to ensure that these patients ful-
filled the following three criteria: (1) typical clinical
features, such as tense blisters on both the normal and
erythematous bases, (2) characteristic histopathologic
findings, such as subepidermal blisters and (3)
immunological findings of positive direct immunoflu-
orescence (DIF) tests (linear IgG and/or C3 deposits
along the epidermal basement-membrane zone). Of
the ninety-seven patients identified as potentially eli-
gible cases, we excluded 20 patients who did not meet
these inclusion criteria, thus the sample for this study
comprised 77 patients. The following data were
recorded: age at diagnosis, gender, degree of autono-
my, clinical features, laboratorial parameters, therapy
adopted, concomitant medications and comorbidities
(neurological and psychiatric disorders, hypertension,
diabetes mellitus, thyroid dysfunction, psoriasis, leg
ulcers or other chronic wounds, history of fracture or
joint-replacement surgery). One hundred and seventy-
six controls (~2 for each BP patient) were randomly
selected from the list of our clinical folders, excluding
patients with a diagnosis of bullous or cutaneous
malignant disease, and matched according to age, sex
and inpatient to outpatient ratio.
Statistical analysis
Statistical analysis was performed using the
Software Package for Statistical Science (SPSS for
Windows, version 18.0, Chicago, IL). Continuous data
are presented as the mean value and standard devia-
tion (SD), and categorical variables are presented as
percentages. Patients and control subjects were com-
pared using the Student’s t-test for continuous vari-
ables, while the Pearson Chi-square test was applied
for categorical variables. Univariate logistic regression
was used to calculate the crude odds ratios (OR) and
95% confidence intervals (CI) for comorbid conditions
in relation to BP. A logistic regression model was used
to measure the association between BP and neurolog-
ical disorders in a multivariate analysis.
RESULTS
The median (range) age at presentation for BP
was 79.6 (SD 8.3) years. The age distribution ranged
from 49 to 96 years. Thirty nine (50.6%) of the patients
were female and 38 (49.4%) were male. The age, age
group and gender distributions of the cohort are pre-
sented in Table 1. Control patients were well matched
in terms of age (p=0.64), gender (p=0.51), and had the
same inpatient to outpatient ratio (p=0.19). Controls
had various cutaneous diseases (erysipela/cellulitis,
leg ulcer, drug eruption, eczema, psoriasis and vas-
culitis), as illustrated in Graph 1.
Characteristic Cases Controls P-value*
n = 77 n = 176 
Age (mean), years 79.6 79.1 0.64 †
Age group, n (%) 0.22 ‡
<60 1 (1.3) 2 (1.1) 
60-69 8 (10.4) 9 (5.1) 
70-79 32 (41.6) 92 (52.3) 
≥ 80 36 (46.7) 73 (41.5) 
Gender, n (%) 0.51¥
♂ 38 (49.4) 79 (44.9) 
♀ 39 (50.6) 97 (55.1) 
Input patients, n (%) 62 (80.5) 128 (72.7) 0.19 ¥
TABLE 1: Demographic features of cases and controls
GRAPH 1: Diseases of the controls
*P- value of the T student test (†), Fisher’s exact test (‡) or Chi-Square test
(¥), as appropriate.
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Complications occurred in 25 patients (32.5 %),
mainly infections (urinary tract infection, respiratory
infection and erysipela/cellulitis) and decompensation
of diabetes, which affected 20.8 and 14.3% of BP
patients, respectively. In 3 patients, the infection pro-
gressed to sepsis, with fatal outcomes for 2 of them. BP
patients who underwent systemic treatment were eight
times more likely to have complications than patients
who only received topical corticosteroids (p< 0.017).
Clinical remission was achieved in a mean of 42.7
days (SD 29). Twenty-two patients were lost to follow-
up. Of the 55 BP patients who were still in follow-up, 27
(49.1%) experienced at least one relapse. The mean
interval until relapse was 4.4 months. BP patients were
kept in follow-up for a mean of 8.5 months (SD 11).
Table 5 shows the univariate comparison of
cases and controls. 44.2% of patients (34 BP) were in a
bedridden condition, compared with 13.6% (24) of the
controls (OR 5.2, 95% CI 2.8-9.8). Also, BP patients had
been hospitalized for a longer period of time com-
pared to controls (mean 20.5 vs 13.2 days, p<0.001).
Eight (11%) BP patients had a prior diagnosis of
malignancy, namely prostate cancer (2 patients) and
lymphoproliferative disorders (2 patients) (data not
shown). No statistical difference was found between
cases and controls.
At least one neurological disease was present in
55.8% (43) of BP cases before the diagnosis of BP com-
pared with 20.5% (36) of controls (OR 5.36, 95% CI
2.97-9.66). BP patients had significantly increased
odds for cerebral stroke (OR 8.10, 95% CI 3.80-17.25),
dementia (OR 5.25, 95% CI 2.71-10.16) and
Parkinson’s disease (OR 4.91, 95% CI 0.88-27.44).
However, the association with Parkinson’s disease
became non-statistically significant after correction for
multiple testing (Table 6).
No association was found between BP and
Alzheimer’s disease, depression and diabetes melli-
tus. Controls were more likely than BP patients to
have hypertension (2.17 odds).
DISCUSSION
We found an association between BP and neu-
rological disorders (dementia and cerebral stroke),
which remained to be independently associated with
BP by multivariate analysis. Parkinson’s disease
missed its association, probably due to the small num-
Chronic treatment with at least one drug before
onset of BP was observed in 87% of cases, namely
diuretics (48.1% of BP patients), angiotensin-convert-
ing enzyme inhibitors/angiotensin II receptors antag-
onists (40.3%) and benzodiazepines (35.1%) (Table 2).
Upon diagnosis, all patients had cutaneous blis-
ters and 34 patients (44.2%) also had urticarial
plaques. In addition, the oral mucosa of 11 patients
(14.3%) were affected, while 92.2% complained of pru-
ritus. About half of the cases involved peripheral
blood eosinophilia (50.6%) (Table 3).
About one fifth of patients (20.8%) was success-
fully treated with high-potency topical steroids in
monotherapy. The rest also received systemic treat-
ment, mainly oral corticosteroids (57.1%). Dapsone was
the second most prescribed systemic drug, alone or
concurrently with oral corticosteroids (Table 4). Some
patients treated with dapsone (11.4%) experienced side
effects: hemolysis and anemia (data not shown).
Chronic medication BP patients (n = 77)
number (%)
Chronic medication 67 (87)
Diuretics 37 (48.1)
Furosemide 21 (27.3)
Thiazides 17 (22)
Spirolactone 2 (2.6)
Angiotensin-converting enzyme inhibitors/angiotensin II
receptor antagonists 31 (40.3)
Benzodiazepines 27 (35.1)
Neuroleptics 24 (31.2)
Antiarrhytmics 14 (18.2)
NSAIDs 5 (6.5)
Calcium channel blockers 4 (5.2)
Statins 4 (5.2)
Fenofibrates 1 (1.3)
TABLE 2: Chronic medication (at least one drug in the last
three months) in BP patients
Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs.
Characteristic Number (%)
n=77
Pruritus 71 (92.2)
Type of lesions
tense blisters 47 (61)
urticarial plaque 34 (44.2)
eczematous lesions 8 (1)
Mucosal lesions 11 (14.3)
Eosinophilia (eosinophil>600 cell/uL) 39 (50.6)
TABLE 3: Clinical characteristic of BP patients
Treatment modalities  n, (%)
Topical corticosteroids 77 (100)
Oral corticosteroids 44 (57.1)
Dapsone 35 (45.5)
Azathioprine 6 (7.7)
Methotrexate 3 (3.9)
TABLE 4: Treatment modalities
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ber of patients in our cohort. Our results confirmed
earlier findings of a higher prevalence of neurological
diseases among BP patients when compared with the
general population. In France, 36% of BP patients
were diagnosed with at least one neurological disor-
der, namely dementia, in 20% of BP patients.8,13
These associations have been widely investigat-
ed in recent years. The hypothesis of immunological
cross-reactivity between the neuronal isoform of
BPAG1 and its epithelial isoform, seems to explain
those associations. Neurological diseases could
expose the neuronal isoform and trigger a subsequent
immunological reaction that causes the cutaneous
lesions. Further studies are needed to better under-
stand the underlying molecular pathways.20
The relationship between BP and malignancy has
been under debate for many years and is still controver-
sial. Some reports have suggested an increased frequency
of certain carcinomas (e.g. stomach, colon, prostate, breast
and lung) as well as lymphoproliferative disorders.12,21-
23 As BP affects predominantly the elderly, it was expected
that there would be a higher frequency of malignancies
than in the general population. In 1990, Venning  et
al reported that the rate of malignant disease was higher
in BP patients (17.9%) compared with matched controls
(5.3%).21 Ogawa et al studied a large Japanese population
of BP patients (1113 patients) and found malignant dis-
ease in 5.8% of patients compared with 0.61% among con-
trols.12 However no statistical analysis was conducted to
clarify these findings. In addition, other authors found no
link between BP and malignancy.24,25 In our control group,
all patients whose reason for consultation or hospital
admission was cutaneous malignancy, were excluded.,
Even removing this bias, we did not find any association
between malignancy and BP. We agree with some authors
who recommend cancer screening when there are sys-
temic manifestations and atypical presentations, such as
onset in a middle-aged person.Also, BP patients should
have regular cancer screening tests as recommended for
the general population.
Chuang  et al reported an association between
BP and diabetes,  showing  20% diabetic BP patients
versus 2.5% diabetic controls (p=0.004).11 This was
supported by other studies.26-27 It has been proposed
that an autoimmune response occurs after exposure of
the BP antigens, by glycation of proteins of the dermo-
epidermal junction. Like other authors, we did not
Cases Controls OR (95% CI)1 P-value2
(n=77) (n=176)
Neurological disease 43 (55.8) 36 (20.5) 5.36 (2.97-9.66) <0.001
Dementia 19 (37.7) 21 (11.9) 5.25 (2.71-10.16) <0.001
Cerebral stroke 27 (35.1) 12 (6.8) 8.10 (3.80-17.25) <0.001
Parkinson’s disease 2 (1.1) 4 (5.2) 4.91 (0.88-27.44) 0.046
Alzheimer’s disease 2 (2.6) 2 (1.1) - -
Depression 8 (10.4) 10 (5.7) - -
Hypertension 45 (58.4) 135 (76.7) 0.46 (0.26-0.83) 0.008
Diabetes mellitus 20 (26.0) 46 (26.1) - -
Ulcers 6 (7.8) 38 (21.6) 0.31 (0.13-0.77)) 0.009
Past fracture or joint-replacement surgery 12 (15.6) 27 (15.3) - -
Malignancy 8 (10.4) 31 (17.6) - -
Chronic medication 67 (87.0) 165 (93.2) - -
Bedridden condition 34 (44.2) 24 (13.6) 5.22 (2.79-9.76) < 0.001
Length of hospitalization (in days, range) 20.5 13.3 - < 0.001
Complications 25 (32.2) 22 (12.5) 2.46 (1.26-4.80) 0.007
TABLE 5: Univariate comparison of cases and controls
1 – Odds ratios with 95% CI. 2 – P-value of the Pearson Chi-square test.
Odds ratios were adjusted for matching variables (age, gender) and neu-
rological disorders.
OR (95% CI) P-value
Dementia 4.13 (1.42-14.56) <0.001
Cerebral stroke 5.22 (1.65-15.51) <0.001
Parkinson’s Disease - 0.148
Age 0.651
Gender 0.619
TABLE 6: Multivariate logistic regression for the association
between neurological disorders and BP patients
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find an association between BP and diabetes.24 Further
studies are needed to clarify this issue.
Systemic corticosteroid treatment is the most
common treatment for BP patients.14 However, BP
treatment is not devoid of side effects and is often
responsible for the exacerbation of associated diseases
in the elderly population. Thus, a careful judgment
should be made before starting any treatment. In our
study, BP patients under systemic treatment experi-
enced more complications compared with those treat-
ed using topical corticosteroids. In this context,
two fatal outcomes occurred. In a previous study, sep-
sis represented the main cause of death in BP
patients.16 It is interesting to note that all patients treat-
ed with topical corticosteroids, in addition to clinical
remission, experienced no major complications.
Our study has some limitations, such as the ret-
rospective chart analysis and the relatively small
number of patients. Further, we could not conclude
anything about BP incidence because a considerable
number of BP patients were not submitted to histolog-
ical and immunofluorescence studies, and therefore
were not included in this study.
CONCLUSIONS
We identified an association between neurologi-
cal diseases and BP in Portuguese patients, supporting
associations found in previous studies. This association
is of interest due to the possible role in BP etiology.
Further research is required to elucidate these findings.
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